Bridge

Bridge strategy to daraxonrasib — preserve function while the window opens.

What is ECOG?

Performance Status

ECOG is a 0–4 scale that describes how much a person's daily activities are affected by their illness. Daraxonrasib requires ECOG 0 or 1 — meaning you are largely independent and mobile. Preserving this is the goal of the bridge strategy.

Fully active

You can carry out all normal activity without restriction.

Restricted but ambulatory

You have some restriction in physical activity but can walk and carry out light work. You can care for yourself.

Ambulatory, self-care only

You can walk and care for yourself but can't do work. Up and about more than 50% of waking hours.

3–4

Limited self-care

Limited ability to care for yourself. Confined to bed or chair more than 50% of waking hours.

Preserve ECOG status

Daraxonrasib requires ECOG 0–1 for trial eligibility. Every point of functional decline narrows the window. This platform watches axis 3 — treatment-driven toxicity — which standard oncology often misses until it's too late to reverse.

Track the three axes

ECOG is shaped by tumour burden (axis 1), cancer-driven symptoms (axis 2), and treatment toxicity (axis 3). Scans cover axis 1. This platform fills the axis 3 gap: neuropathy, sarcopenia, fatigue trends, and functional tests like grip and gait speed.

The window

RASolute 302 enrollment closes June 2026. FDA accelerated approval may open expanded access earlier. The goal of first-line GnP is not maximum response — it is arriving at the second-line window with enough functional reserve to enter it.